コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 generalizability across murine cohorts with pancreatic disease.
2 of Health in Pomerania who had no history of pancreatic disease.
3 Heterozygotes also develop adult-onset pancreatic disease.
4 pulmonary injury, even in the face of severe pancreatic disease.
5 ic lung cancer without evidence of recurrent pancreatic disease.
6 isease, gastrointestinal bleeding, liver and pancreatic disease.
7 s known about VNTR single-base insertions in pancreatic disease.
8 potential immunotherapy target for treating pancreatic disease.
9 les versus healthy controls and noncancerous pancreatic disease.
10 from healthy donors and patients with benign pancreatic disease.
11 in the ducts, which could otherwise lead to pancreatic disease.
12 T protein causes both exocrine and endocrine pancreatic disease.
13 tantially improve diagnosis and treatment of pancreatic disease.
14 considered an irreversible fibroinflammatory pancreatic disease.
15 rimed" aPSC to contribute to the severity of pancreatic disease.
16 gene class hierarchical correlations seen in pancreatic disease.
17 ed with increased serum IgG4 and unexplained pancreatic disease.
18 ulinism (CHI) may be due to diffuse or focal pancreatic disease.
19 e impact of CD39 gene deletion in a model of pancreatic disease.
20 ing controversy over endoscopic treatment of pancreatic disease.
21 imaging or laboratory findings indicative of pancreatic disease.
22 atography for many diagnostic indications in pancreatic disease.
23 e samples to map the cellular foundations of pancreatic diseases.
24 l microbiota and guide patient management in pancreatic diseases.
25 iomarker discovery in endocrine and exocrine pancreatic diseases.
26 ges from patients belonging to six different pancreatic diseases.
27 ic function, with potential implications for pancreatic diseases.
28 of patients with malignant and nonmalignant pancreatic diseases.
29 tro organogenesis and tissue engineering for pancreatic diseases.
30 illion individuals and 119 000 patients with pancreatic diseases.
31 hanisms involved in the development of human pancreatic diseases.
32 ion in the treatment of benign and malignant pancreatic diseases.
33 s network will increase our understanding of pancreatic diseases.
34 ll proliferation during normal growth and in pancreatic diseases.
35 phagy, and their deregulation by obesity, in pancreatic diseases.
36 facilitates the induction and progression of pancreatic diseases.
37 eatic cancer, chronic pancreatitis, or other pancreatic diseases.
38 sis could improve our understanding of human pancreatic diseases.
39 overy and treatment as well as prevention of pancreatic diseases.
40 the use of in vivo muMRI in mouse models of pancreatic diseases.
41 islet cells, and that are relevant to human pancreatic diseases.
42 thyroid, parathyroid, adrenal and endocrine pancreatic diseases.
43 aphy related to the diagnosis and therapy of pancreatic diseases.
44 will help with the diagnosis and staging of pancreatic diseases.
45 ill help refine the diagnosis and staging of pancreatic diseases.
46 ce from 1/7 (17%) of the patients with other pancreatic diseases.
47 with juice samples from patients with other pancreatic diseases.
48 the exocrine pancreas, 4) genetic drivers of pancreatic diseases, 5) tools for integrated pancreatic
49 rgically from 155 individuals with suspected pancreatic disease: 56 patients had pancreatic ductal ad
50 isease, 4 (7.4%) on gastroscopy, 4 (7.4%) on pancreatic disease and 2 (3.7%) on endoscopic sedation/E
51 y utilized for staging cancer, assessment of pancreatic disease and evaluation of submucosal lesions.
52 -9 was able to discriminate PDAC from benign pancreatic disease and healthy individuals, and was prog
53 nical observations relating to management of pancreatic disease and investigations of pancreatic func
54 rols) with no imaging findings suggestive of pancreatic disease and normal amylase and lipase who und
55 ive in early pancreatic development on adult pancreatic disease and traits is not well understood.
57 e pancreas will shed light in the origins of pancreatic diseases and may suggest novel therapeutic ap
58 which has been shown to co-occur with other pancreatic diseases and neoplasms with certain attribute
59 toward understanding the etiopathologies of pancreatic diseases and the development of novel therape
61 ith pancreatic adenocarcinoma, 15 with other pancreatic diseases) and the serum HIP/PAP-I levels in 9
62 pancreatitis, 12 controls lacked evidence of pancreatic disease, and 44 were asymptomatic individuals
64 enetically engineered mouse models and human pancreatic disease, and that it will be broad enough to
67 oposed to be a powerful tool in the study of pancreatic disease, as well as a potential source for ce
75 that up-regulation of anionic trypsinogen in pancreatic diseases does not affect physiological trypsi
77 healthy subjects and patients with a benign pancreatic disease from patients with early- and late-st
80 e past year, major advances in understanding pancreatic disease have been made through the tools of m
86 accelerate and improve the quantification of pancreatic disease in animal studies and become a unifyi
87 e trypsinogen (IRT), a biomarker of exocrine pancreatic disease in cystic fibrosis (CF), is elevated
89 istoarchitectural structures, as we show for pancreatic disease in living mice, for chronic kidney di
90 ore extensive investigation of patients with pancreatic diseases in Bangladesh, including non-insulin
91 compare the incidence and mortality of major pancreatic diseases in high-quality population-based coh
98 ewborn IRT measure would reflect more severe pancreatic disease, including compromised islet compartm
99 ation increases the risk of several forms of pancreatic disease, including fibrocalculous pancreatic
100 chniques and their role in the management of pancreatic diseases, including acute and chronic pancrea
102 nding of the molecular mechanisms underlying pancreatic diseases, including pancreatitis and cancer,
103 ding of the genesis and progression of human pancreatic diseases, including PDAC, is limited because
104 are involved in several pathologies, such as pancreatic diseases, inflammation, fibrinolysis, and can
105 with trauma/burn injuries, surgery, cancer, pancreatic disease, inflammatory bowel disease, critical
108 branes, leading to chronic lung and exocrine pancreatic disease--is less common in African-Americans
109 ancreatic carcinoma than in those with other pancreatic diseases, it may be a useful indicator of the
110 pancreatic acinar induces several important pancreatic disease manifestations not previously reporte
111 sting in vivo potential functions of PAK4 in pancreatic disease models such as for pancreatitis and d
112 and control subjects without ADPKD or known pancreatic disease (n = 110) who were matched for age, s
113 ncer patients (n = 61), patients with benign pancreatic disease (n = 31), and healthy control subject
114 clinical significance of non-alcoholic fatty pancreatic disease (NAFPD) or fatty pancreas is largely
116 n vitro studies, and publications focused on pancreatic diseases other than chronic pancreatitis.
120 cellular and tissue changes associated with pancreatic disease, serving as a mode of improved detect
121 a history of gallstones or chronic liver or pancreatic diseases, SIRs were 1.36 (95% CI, 1.17-1.57)
122 induction of an activated state observed in pancreatic disease such as chronic pancreatitis and panc
123 adenocarcinoma (PDAC) from those with benign pancreatic diseases such as chronic pancreatitis and int
126 DAC signature against a background of benign pancreatic diseases that yielded an 89% prediction accur
127 igations further elucidated risk factors for pancreatic disease, the natural history of alcoholic pan
128 fine-needle aspiration in diagnosing various pancreatic diseases; the role of endoscopic ultrasound-g
129 er support the view that CEL mutations cause pancreatic disease through protein misfolding and proteo
130 betes (T2D) predisposes patients to exocrine pancreatic diseases through (epi)genetic mechanisms.
131 patients who had or were suspected of having pancreatic disease underwent dual-phase helical CT.
134 tients and 50 randomly selected controls (no pancreatic disease) were analyzed, and IPF data were cor
135 completely protect mice from both heart and pancreatic disease when mice are challenged 28 days p.i.
138 bally, acute pancreatitis is the most common pancreatic disease whilst pancreatic cancer is the most
139 18 years and older, without known biliary or pancreatic disease, who were fasting to undergo routine
140 ; it occurs because of a variety of exocrine pancreatic diseases with varying mechanisms of hyperglyc
141 Plastic stents predominate in patients with pancreatic disease, with the exception of transmural dra
142 f the Exocrine and Endocrine Compartments in Pancreatic Diseases workshop was a 1.5-day scientific co